Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2003
09/04/2003WO2001085193A3 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
09/04/2003WO2001066595A9 Human fgf-23 gene and gene expression products
09/04/2003WO2001057261A9 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
09/04/2003US20030167486 Double transgenic mice overexpressing human beta secretase and human APP-London
09/04/2003US20030167033 Systems and methods for photodynamic therapy
09/04/2003US20030166927 1,5-Benzothiazepines and their use as hypolipidaemics
09/04/2003US20030166902 Hybrid; process control; genetic engineering
09/04/2003US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents
09/04/2003US20030166897 Diagnosis, therapy cancer; transgenic animal
09/04/2003US20030166883 Genetic engineering; drug screening
09/04/2003US20030166877 Reducing the immunogenicity of fusion proteins
09/04/2003US20030166859 Controlling cell proliferation, cell differentiation; anticancer agents
09/04/2003US20030166851 Contacting a polypeptide (Transmembrane serin protease 9) with a substrate that is proteolytically cleaved by the polypeptide, adding a test compound, measuring the amount of substrate cleaved in the presence of test compound
09/04/2003US20030166847 Novel human leptin receptor gene-related protein
09/04/2003US20030166724 For treating or delaying progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, cardiac arrhythmia
09/04/2003US20030166720 Administering a therapeutic combination comprising a first amount of a fibric acid derivative and a second amount of a cholesteryl ester transfer protein inhibitor effective for treatment of hyperlipidemic conditions
09/04/2003US20030166712 Combinations of cholesteryl ester transfer protein inhibitors and HMG CoA reductase inhibitors for cardiovascular indications
09/04/2003US20030166710 A cylic peroxide containing methyl carboxylic acid or ester; anticarcinogenic agent
09/04/2003US20030166696 Pramipexole for the treatment of HIV dementia
09/04/2003US20030166690 Use of compounds for decreasing activity of hormone-sensitive
09/04/2003US20030166685 Acid derivatives of benzene useful as anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer
09/04/2003US20030166662 Administering a selective cyclic guanosine monophosphate (cGMP) phosphodiesterase 5 (PDE5) inhibitor, e.g. Rezulin, Avandia, Actos; hypotensive, antidiabetic and hypoglycemic agents; gout; anticoagulants; atherosclerosis; obesity
09/04/2003US20030166661 Administering a synergistic mixture of L-arginine and a type V phosphodiesterase enzyme inhibitor as an antispasmodic agent to induce vasodilation; treating of cardiac pathologies as well as sexual disorders such as erectile dysfunction
09/04/2003US20030166660 Administering a synergistic mixture of Imatinab and a telomerase inhibitor, e.g., telomestatin, for the delay of progression or treatment of leukemia or Imatinib-resistant leukemia; antiproliferative agents
09/04/2003US20030166644 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
09/04/2003US20030166642 Administering synergistic mixtures of phenothiazine and pentamidine derivatives as anticarcinogenic agents
09/04/2003US20030166632 Method for treating a disease or condition responsive to opening of C1C-2 channel
09/04/2003US20030166631 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
09/04/2003US20030166598 Such as 1,4-benzodiazipines; gene therapy; anticancer agents
09/04/2003US20030166592 For treatment of metabolic disorders (diabetes, obesity)
09/04/2003US20030166591 Testosterone-repressed prostate message-2 (TRPM-2); gene expression inhibition; increased antitumor activity
09/04/2003US20030166585 Substituted tetracycline compounds as synergistic antifungal agents
09/04/2003US20030166584 For treatment of intestinal/hepatic cancer; improved drug delivery
09/04/2003US20030166578 Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
09/04/2003US20030166568 Organic compounds
09/04/2003US20030166565 CD antigens; for regulating inflammation; nuclear magnetic resonance; drug screening
09/04/2003US20030166562 Treatment for asthma or allergies
09/04/2003US20030166553 Compositions for preventing and treating digestive organs diseases
09/04/2003US20030166546 Uses of THANK, a TNF homologue that activates apoptosis
09/04/2003US20030166545 Compounds and use thereof to modify transport across cell membranes
09/04/2003US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide
09/04/2003US20030166535 Preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.
09/04/2003US20030166534 Suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes,
09/04/2003US20030166527 Granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs.
09/04/2003US20030166521 Inhibition of thrombosis by treatment with P-selectin antagonists
09/04/2003US20030166516 Methods of treating, preventing, or inhibiting inflammation with exumolide compounds
09/04/2003US20030166258 Saccharomyces cerevisiae yeast strain with functional expression of a glut transporter
09/04/2003US20030166239 Bone morphogenic proteins; for regulating bone homeostasis, adiposity, and calcification of atherosclerotic plaques
09/04/2003US20030166221 Megakaryocyte tyrosine kinases; signal transduction in hematopoietic cells
09/04/2003US20030166219 Mitogen-activated protein/extracellular signal-regulated kinases (MAP/ERK)
09/04/2003US20030166189 Peptide of given amino acid sequence; sulfotransferases; useful in labeling agents with tagged sulfur, diagnosis/treatment of cancer, hypertension, renal and neurodegenerative diseases
09/04/2003US20030166187 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
09/04/2003US20030166175 Process for clavulanic acid production
09/04/2003US20030166164 IL-17 like molecules and uses thereof
09/04/2003US20030166155 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/04/2003US20030166154 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof
09/04/2003US20030166153 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/04/2003US20030166151 Comprises peptides of ionotropic glutamate receptor for diagnosing and treating nervous system disorders; drug screening
09/04/2003US20030166150 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
09/04/2003US20030166045 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant
09/04/2003US20030166044 Novel proteins
09/04/2003US20030166024 Nucleotide sequences coding monoclonal antibody for the prevention, treatment and diagnosis of viral, inflammatory and tumor diseases; gene therapy
09/04/2003US20030166016 Assay methods for cyclin dependent kinases
09/04/2003US20030165950 Inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in
09/04/2003US20030165820 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
09/04/2003US20030165809 MARKs as modifiers of the p53 pathway and methods of use
09/04/2003US20030165807 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
09/04/2003US20030165585 Xanthine-containing compositions for oral administration and uses related thereto
09/04/2003US20030165576 Antitumor effect potentiators
09/04/2003US20030165545 Contact lenses; mixture of oil, water and surfactants
09/04/2003US20030165519 Administering complex of protein taken from original tumor
09/04/2003US20030165510 Antiinflammatory agents; anticancer agents; cholesterol binding protein
09/04/2003US20030165503 Vaccine for the treatment of atherosclerosis
09/04/2003US20030165501 Protein antagonist; insulin resistance; muscle disorders
09/04/2003US20030165499 Compositions and methods for treating psoriasis
09/04/2003US20030165497 RRP sequences and knockout mice and uses thereof
09/04/2003US20030165491 Anticancer agents; controlling cell differentiation; complexing; insertion plasmids; genetic engineering
09/04/2003US20030165490 22196, a novel human aminopeptidase
09/04/2003US20030165486 Compositions and methods for the induction of retinal detachments
09/04/2003US20030165460 Proteins which control cell differentiation; immunology response; antiinflammatory agents; wound healing agents
09/04/2003US20030165457 Analgesics; antiinflammatory agents; antiischemic agents; antiscarring agents; wound healing agents
09/04/2003US20030165449 Lipase inhibiting composition
09/04/2003US20030165437 Aerosos formulations containing P134a and particulate medicament
09/04/2003US20030165436 Formulations for use in inhaler devices
09/04/2003CA2503094A1 Therapeutic methods for acute myeloid leukemia
09/04/2003CA2477726A1 Use of tyrosine kinase inhibitors for treating substance use disorders
09/04/2003CA2477558A1 N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/04/2003CA2477347A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
09/04/2003CA2477328A1 Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents
09/04/2003CA2477253A1 Compositions and method for regulation of calcium-dependent signalling in brain
09/04/2003CA2477249A1 Novel type-1 cytokine receptor glm-r
09/04/2003CA2477231A1 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
09/04/2003CA2477225A1 Novel compositions and methods for cancer
09/04/2003CA2477178A1 Administration of agents for the treatment of inflammation
09/04/2003CA2477111A1 Use of tyrosine kinase inhibitors for treating cns disorders
09/04/2003CA2477105A1 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
09/04/2003CA2477038A1 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
09/04/2003CA2477005A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
09/04/2003CA2476994A1 Methods of extending corneal graft survival
09/04/2003CA2476896A1 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
1 ... 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 ... 1151